
Dydrogesterone
CAS No. 152-62-5
Dydrogesterone ( —— )
产品货号. M27963 CAS No. 152-62-5
地屈孕酮是一种有效的孕激素,可用于孕激素缺乏症的研究。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥421 | 有现货 |
![]() ![]() |
5MG | ¥680 | 有现货 |
![]() ![]() |
10MG | ¥1126 | 有现货 |
![]() ![]() |
25MG | ¥2341 | 有现货 |
![]() ![]() |
50MG | ¥3750 | 有现货 |
![]() ![]() |
100MG | ¥5532 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Dydrogesterone
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述地屈孕酮是一种有效的孕激素,可用于孕激素缺乏症的研究。
-
产品描述Dydrogesterone is a potent progestogen which can be used in progesterone deficiency studies.(In Vitro):Dydrogesterone is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens.
-
体外实验Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency. Although similar in molecular structure and pharmacological effects to endogenous progesterone. It is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens. Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counteract the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone.
-
体内实验——
-
同义词——
-
通路Microbiology/Virology
-
靶点Filovirus
-
受体THR-β
-
研究领域——
-
适应症——
化学信息
-
CAS Number152-62-5
-
分子量312.45
-
分子式C21H28O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 33.33 mg/mL (106.67 mM)
-
SMILESC[C@](CC[C@H]1[C@]2(C)CC3)([C@@H](CC4)[C@@H]1C=CC2=CC3=O)[C@H]4C(C)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Cable EE, et al. Reduction of hepatic steatosis in rats and mice after treatment with aliver-targeted thyroidhormone receptor agonist. Hepatology. 2009 Feb;49(2):407-17.